# This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity

> **NCT06536023** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Adolescents With Obesity

## Interventions

- **DRUG:** IBI362
- **DRUG:** IBI362 placebo

## Key facts

- **NCT ID:** NCT06536023
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-30
- **Primary completion:** 2025-07-22
- **Final completion:** 2025-08-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06536023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06536023, "This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06536023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*